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Background: Platelet activation is relevant to a variety of coronary heart diseases. Our previous studies revealed
that sesamol possesses potent antiplatelet activity through increasing cyclic AMP formation. Although platelets are
anucleated cells, they also express the transcription factor, NF-B, that may exert non-genomic functions in platelet
activation. Therefore, we further investigated the inhibitory roles of sesamol in NF-B-mediated platelet function.
Methods: Platelet aggregation, Fura 2-AM fluorescence, and immunoblotting analysis were used in this study.
Results: NF-B signaling events, including IKKb phosphorylation, IBa degradation, and p65 phosphorylation, were
markedly activated by collagen (1 μg/ml) in washed human platelets, and these signaling events were attenuated
by sesamol (2.5~25 μM). Furthermore, SQ22536 and ODQ, inhibitors of adenylate cyclase and guanylate cyclase,
respectively, strongly reversed the sesamol (25 μM)-mediated inhibitory effects of IKKb phosphorylation, IBa
degradation, and p65 phosphorylation stimulated by collagen. The protein kinase A (PKA) inhibitor, H89, also
reversed sesamol-mediated inhibition of IBa degradation. Moreover, BAY11-7082, an NF-B inhibitor, abolished
IBa degradation, phospholipase C (PLC)g2 phosphorylation, protein kinase C (PKC) activation, [Ca
2+]i mobilization,
and platelet aggregation stimulated by collagen. Preincubation of platelets with the inhibitors, SQ22536 and H89,
both strongly reversed sesamol-mediated inhibition of platelet aggregation and [Ca
2+]i mobilization.
Conclusions: Sesamol activates cAMP-PKA signaling, followed by inhibition of the NF-B-PLC-PKC cascade, thereby
leading to inhibition of [Ca
2+]i mobilization and platelet aggregation. Because platelet activation is not only linked
to hemostasis, but also has a relevant role in inflammation and metastasis, our data demonstrating that inhibition
of NF-B interferes with platelet function may have a great impact when these types of drugs are considered for
the treatment of cancer and various inflammatory diseases.
Keywords: I?κ?Ba?α?, IKK, intracellular Ca
2+, protein kinase A, platelet activation, sesamol
Background
Sesamol (3,4-methylenedioxyphenol) is a constituent of
roasted sesame seeds, Sesamum indicum L., an impor-
tant oilseed crop [1]. Sesamol is a potent phenolic anti-
oxidant contained only in processed sesame oil. Several
beneficial effects of sesamol were reported including
antioxidation, chemoprevention, antimutagenic, and
antihepatotoxic properties [2-5]. Traditionally, sesame
seed oil was used to remove wrinkles and prevent aging,
when applied in a facial massage to the skin [5].
Recently, sesamol was found to induce growth arrest
and apoptosis in cancer and cardiovascular cells [6].
Sesamol was also found to enhance vascular fibrinolytic
capacity through regulating gene expression of a plasmi-
nogen activator and nitric oxide (NO) release in
endothelial cells [7,8].
Arterial thrombosis is quite distinct from venous
thrombosis in that arterial thrombosis is mostly com-
posed of platelets that adhere to ruptured endothelial
surfaces [9]. Venous thrombosis, which is enriched in
fibrin and erythrocytes, can occur in the absence of ves-
sel wall damage. Therefore, platelet aggregation may
play a crucial role in the atherothrombotic process [10].
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development of acute thrombosis, coronary heart dis-
eases (CHDs), and atherosclerosis, no data are available
concerning the effect of sesamol on platelet activation.
Recently, we reported that sesamol exhibited potent
activity of inhibiting platelet aggregation [11]. Its
mechanism may involve an increase in the cAMP-
endothelial NO synthase (eNOS)/NO-cGMP pathway,
followed by inhibition of the phospholipase Cg2
(PLCg2)-protein kinase C (PKC)-p38 mitogen-activated
protein kinase (MAPK)-thromboxane A2 cascade,
thereby leading to inhibition of [Ca
2+]i mobilization, and
finally inhibition of platelet aggregation [11].
In the present study, we further investigated the
mechanisms of sesamol in inhibiting platelet activa-
tion in greater detail, and found that sesamol
obviously suppressed nuclear factor-kappa B (NF-B)-
mediated signaling events in washed human platelets.
NF-B, a transcription factor, regulates diverse cell
functions ranging from inflammation to cell death. As
the term, “nuclear factor” implies, the actions of NF-
B require its translocation from the cytosol to the
nucleus to bind cognate nuclear DNA sequences. Pla-
telets are anucleated, do not differentiate or prolifer-
ate, and thus are a good model for studying non-
genomic functions of NF-B in sesamol-mediated
inhibition of NF-B activation. We therefore for the
first time examined the cellular NF-B signaling








5-isoquinolinesulfonamide dihydrochloride (H89), and
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ)
were purchased from Sigma Chemical (St Louis, MO,
USA); Fura 2-AM was from Molecular Probe (Eugene,
OR, USA); the anti-phospho-IKKa (Ser
180)/IKKb (Ser
181)
polyclonal antibody (pAb), anti-IBa (44D4) pAb, anti-
PLCg2, anti-phospho (Tyr
759) PLCg2 monoclonal antibo-
dies (mAbs), anti-phospho (Ser) PKC substrate (p47)
pAb, and the anti-phospho-NF-B p65 (Ser
536) pAb were
from Cell Signaling (Beverly, MA, USA); the anti-a-tubu-
lin mAb was from NeoMarkers (Fremont, CA, USA); and
the Hybond-P polyvinylidene difluoride (PVDF) mem-
brane, enhanced chemiluminescence (ECL) Western
blotting detection reagent and analysis system, horserad-
ish peroxidase (HRP)-conjugated donkey anti-rabbit
immunoglobulin G (IgG), and sheep anti-mouse IgG
were from Amersham (Buckinghamshire, UK). Sesamol
was dissolved in 0.5% dimethyl sulfoxide (DMSO) and
stored at 4°C until used.
Platelet aggregation
Human platelet suspensions were prepared as previously
described [10]. This study was conducted according to
the guidelines laid down in the Declaration of Helsinki
and all procedures involving human subjects were
approved by the Institutional Review Board of Taipei
Medical University, and all human volunteers provided
informed consent. In brief, blood was collected from
healthy human volunteers who had taken no medicine
during the preceding 2 weeks, and was mixed with acid/
citrate/glucose (9:1; v/v). After centrifugation at 120 g for
10 min, the supernatant (platelet-rich plasma; PRP) was
supplemented with PGE1 (0.5 μM) and heparin (6.4 IU/
ml), and then incubated for 10 min at 37°C and centri-
fuged at 500 g for 10 min. The platelet pellets were sus-
p e n d e di n5m lo fT y r o d e ’s solution, pH 7.3 [containing
(mM) NaCl 11.9, KCl 2.7, MgCl2 2.1, NaH2PO4 0.4,
NaHCO3 11.9, and glucose 11.1], then apyrase (1.0 U/
ml), PGE1 (0.5 μM), and heparin (6.4 IU/ml) were added,
and the mixture was incubated for 10 min at 37°C. After
centrifugation of the suspensions at 500 g for 10 min, the
washing procedure was repeated. The washed platelets
were finally suspended in Tyrode’s solution containing
bovine serum albumin (BSA) (3.5 mg/ml) and adjusted to
about 4.5 × 10
8 platelets/ml. The final concentration of
Ca
2+ in the Tyrode’s solution was 1 mM.
A turbidimetric method was applied to measure plate-
let aggregation [10], using a Lumi-Aggregometer (Pay-
ton, Scarborough, Ontario, Canada). Platelet suspensions
(3.6 × 10
8 platelets/ml) were preincubated with various
concentrations of sesamol or inhibitors for 3 min before
the addition of collagen (1 μg/ml). The reaction was
allowed to proceed for 6 min, and the extent of aggrega-
tion was expressed in light-transmission units.
Measurement of platelet [Ca
2+]i mobilization by Fura 2-
AM fluorescence
Citrated whole blood was centrifuged at 120 g for 10 min.
The PRP was incubated with Fura 2-AM (5 μM) for 1 h.
Washed platelets (8 × 10
8 platelets/ml) were then pre-
pared as described above. Finally, the external Ca
2+ con-
centration of the platelet suspensions was adjusted to 1
mM. The rise in the [Ca
2+]i was measured using a fluor-
escence spectrophotometer (CAF 110, Jasco, Tokyo,
Japan) with excitation wavelengths of 340 and 380 nm,
and an emission wavelength of 500 nm [10].
Immunoblotting study
Washed platelets (1.2 × 10
9/ml) were preincubated with
sesamol (2.5~25 μM) or various inhibitors for 3 min,
followed by the addition of collagen (1 μg/ml) to trigger
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Page 2 of 10platelet activation. The reaction was stopped, and plate-
lets were immediately re-suspended in 200 μlo fl y s i s
buffer (50 mM Hepes, 5 mM EDTA, 50 mM NaCl, 1%
triton X-100, 10 μg/ml aprotinin, 1 mM phenylmethyl-
sulfonylfluoride, 10 μg/ml leupeptin, 10 mM NaF, 1 mM
sodium orthovanadate, 5 mM sodium pyrophosphate,
and 2 mM dithiothreitol) for 1 h. Lysates were centri-
fuged at 5000 g for 5 min. Samples containing 80 μgo f
protein were separated by sodium dodecylsulfate polya-
crylamide gel electrophoresis (SDS-PAGE) (12%); pro-
teins were electrotransferred by a semidry transfer
method (Bio-Rad, Hercules, CA). Blots were blocked
with TBST (10 mM Tris-base, 100 mM NaCl, and
0.01% Tween 20) containing 5% BSA for 1 h and then
probed with various primary antibodies (diluted 1:1000
in TBST). Membranes were incubated with HRP-linked
anti-mouse IgG or anti-rabbit IgG (diluted 1:3000 in
TBST) for 1 h. Immunoreactive bands were detected by
an ECL system. The bar graph depicts the ratios of
semiquantitative results obtained by scanning reactive
bands and quantifying the optical density using video-
densitometry (Bio-profil; Biolight Windows Application
V2000.01; Vilber Lourmat, France).
Determination of lactate dehydrogenase (LDH)
In brief, washed platelets (3.6 × 10
8/ml) were preincu-
bated with Tyrode’s solution, solvent control (0.5%
DMSO), and various concentrations of sesamol (5~100
μM) for 20 min at 37°C, a 10-μl aliquot of supernatant
was deposited on a Fuji Dri-Chem slide LDH-PIII (Fuji,
Tokyo, Japan), and the absorbance wavelength was read
at 540 nm using an ultraviolet-visible recording spectro-
photometer (UV-160; Shimazu, Japan). A maximal value
(MAX) of LDH was observed from sonicated platelets.
Data analysis
The experimental results are expressed as the means ±
S.E.M. and are accompanied by the number of observa-
t i o n s( n ) .V a l u e so fn refer to the number of experi-
ments, each made with different blood donors. All
experiments were assessed by an analysis of variance
(ANOVA). If this analysis indicated significant differ-
ences among group means, then each group was com-
pared using the Newman-Keuls method. p< 0.05 was
considered statistically significant.
Results
Concentration- and time-dependent effects of sesamol on
collagen-induced NF-B activation in washed human
platelets
In our previous report [11], sesamol (1~5 μM) exhibited
potent activity of inhibiting platelet aggregation stimu-
lated by collagen (1 μg/ml); it also significantly inhibited
platelet aggregation stimulated by arachidonic acid (AA)
(60 μM) at higher concentrations (5~10 μM). In the
present study, we used collagen as an agonist to further
explore the inhibitory mechanisms of sesamol in platelet
activation. The pleiotropic NF-B normally exists as an
inactive cytoplasmic complex, the predominant form of
which is a heterodimer composed of p50 and p65 subu-
nits tightly bound to inhibitory proteins of the IB
family [12]. Once phosphorylated by the IBk i n a s e
(IKK) complex, IB dissociates from NF-B subunits
and is ubiquitinated and rapidly degraded by the protea-
some [12]. IKK phosphorylation was proposed as being
a major mode for IBa degradation, leading to NF-B
activation [12]. As shown in Figure 1A, IKKb phosphor-
ylation significantly increased 3 min after being stimu-
lated by collagen (1 μg/ml) in washed platelets. The
compiled data of Figure 1A are shown at the bottom.
Pretreatment of platelets with various concentrations of
sesamol (2.5~25 μM) concentration-dependently attenu-
ated collagen-induced IKKb phosphorylation (Figure
1A). Based on the above results indicating that sesamol’s
attenuation of IKKb phosphorylation may interfere with
the IKK-IBa cascade, we sought to further examine
whether sesamol interferes with IBa degradation.
Treatment with collagen caused the rapid, time-depen-
dent disappearance of the immunoreactive bands of
IBa (Figure 1B). The IBa protein was markedly
degraded within 10 min, and reached maximal degrada-
tion at 30 min after collagen stimulation. Sesamol
(2.5~25 μM) concentration-dependently reversed the
degradation of IBa protein at 10 min after collagen sti-
mulation (Figure 1C). These results suggest that IKKb
phosphorylation and subsequent IBa degradation in
collagen-stimulated platelets may contribute to sesamol’s
inhibitory actions on NF-B signaling. In addition, the
lactate dehydrogenase (LDH) study revealed that sesa-
mol (5~100 μM) incubated with platelets for 20 min did
not significantly increase LDH activity, even at a higher
concentration (100 μM) (Figure 1D), indicating that
sesamol did not affect platelet permeability or induce
platelet cytolysis, it clearly shows that no cytotoxic
effects of sesamol on platelets at these concentrations.
The roles of cyclic nucleotides in sesamol-mediated
inhibition of NF-B signaling
In our previous description [11], sesamol increased
levels of both cAMP and cGMP, suggesting that
increased cAMP stimulated eNOS activity and NO bio-
synthesis, followed by increasing cGMP formation.
cAMP is the upstream regulator of the eNOS-NO-
cGMP cascade in sesamol-mediated antiplatelet effects.
To investigate whether sesamol-mediated inhibition of
NF-B activation was also regulated by cyclic nucleo-
tides, especially cAMP, we used two different cyclic
nucleotide inhibitors, SQ22536 (100 μM) that inhibits
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Page 3 of 10adenylate cyclase and ODQ (20 μM) an inhibitor of gua-
nylate cyclase. Both inhibitors strongly reversed the
sesamol (25 μM)-mediated inhibition of IKKb phosphor-
ylation (Figure 2A) and IBa degradation (Figure 2B)
stimulated by collagen in washed platelets. In addition,
Liu et al. [13] showed that platelets express three mem-
bers of the NF-B pathway: IKK, IB, and NF-Bp 6 5 .
T h ep r e s e n ts t u d ya l s od e m o n s t r a t e dt h a tp 6 5p h o s -
phorylation was markedly increased, and sesamol (2.5
and 25 μM) concentration-dependently attenuated p65
phosphorylation in platelets stimulated by collagen (1
μg/ml) (Figure 2C). In the presence of SQ22536 (100
μM) and ODQ (20 μM), both inhibitors clearly reversed
the sesamol (25 μM)-mediated inhibition of p65 phos-
phorylation (Figure 2C).
The effects of cyclic nucleotides are mediated via their
respective protein kinase (i.e., PKA, a specific cAMP-
dependent protein kinase), which phosphorylates sub-
strate proteins involved in platelet inhibitory pathways
[14]. To investigate whether sesamol’si n h i b i t i o no fN F -
B was regulated by PKA, a PKA inhibitor (H89) that
inhibits ATP binding to PKA catalytic subunits (PKAc)
was used. As shown in the Figure 2D, H89 (5 μM)
exhibited a similar effect as SQ22536 (100 μM) in rever-
sing the sesamol-mediated inhibition of IBa
degradation.
The roles of NF-B in regulating the PLCg2-PKC cascade
in platelets
A sd e s c r i b e dp r e v i o u s l y[ 1 1 ] ,w es u g g e s tt h a ts e s a m o l
may increase the level of cAMP, followed by inhibition of
the PLCg2-PKC cascade, thereby leading to inhibition of
[Ca
2+]i mobilization, and finally inhibition of platelet
aggregation. PLC hydrolyzes phosphatidylinositol 4,5-
bisphosphate (PIP2) to generate two secondary messen-
gers: inositol 1,4,5-trisphosphate (IP3) and diacylglycerol
(DAG) [15]. DAG activates PKC, inducing 40~47-kDa
protein phosphorylation. To further establish the cellular
signaling events of NF-B associated with the PLCg2-
PKC cascade in sesamol-mediated inhibition of platelet
activation, an NF-B inhibitor, BAY11-7082, which is an
irreversible inhibitor of IBa phosphorylation was used
[16]. The immunoblotting analysis revealed that treat-
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Figure 1 Effects of sesamol on IKKb phosphorylation and IBa
degradation in collagen-activated platelets. Washed platelets (1.2
×1 0
9/ml) were preincubated with or without sesamol (2.5~25 μM)
or a solvent control (0.5% DMSO), followed by the addition of
collagen (1 μg/ml) to trigger (A) IKKb phosphorylation for 3 min or
(B)I Ba degradation for the indicated times (3~30 min), and (C)
IBa degradation for 10 min. Cells were collected, and subcellular
extracts were analyzed as described in “Methods”. For the lactate
dehydrogenase (LDH) experiment (D), washed platelets (3.6 × 10
8/
ml) were preincubated with Tyrode’s solution, solvent control (0.5%
DMSO), and various concentrations of sesamol (5~100 μM) for 20
min at 37°C, a 10-μl aliquot of supernatant was deposited on a Fuji
Dri-Chem slide LDH-PIII as described in “Methods”. Data are
presented as the means ± S.E.M. (n = 4). *p< 0.05 and ***p< 0.001,
compared to the control group (resting);
#p< 0.05,
##p< 0.01, and
###p< 0.001, compared to the collagen group.
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Page 4 of 10dependently abolished IBa degradation (Figure 3A) and
PLCg2 phosphorylation (Figure 3B) stimulated by col-
lagen (1 μg/ml). When collagen was added to human pla-
telets, a protein with an apparent molecular weight of 47
kDa (p47) was predominately phosphorylated compared
to resting platelets (Figure 3C). BAY11-7082 (10 and 50
μM) also abolished p47 phosphorylation, indicating that
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Figure 2 Cyclic nucleotide-dependent inhibition of IKKb phosphorylation, IBa degradation, and p65 phosphorylation by sesamol in
collagen-activated platelets. Washed platelets (1.2 × 10
9/ml) were preincubated with sesamol (2.5 and 25 μM) or a solvent control (0.5%
DMSO) in the absence or presence of SQ22536 (100 μM), ODQ (20 μM), or H89 (5 μM), followed by the addition of collagen (1 μg/ml) to trigger
(A) IKKb phosphorylation for 3 min or (B and D)I Ba degradation and (C) p65 phosphorylation for 10 min. Cells were collected, and subcellular
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Page 5 of 10The functional relevance of NF-B in [Ca
+2]i mobilization
and platelet aggregation
To demonstrate the physiological relevance of NF-Bi n
platelet activation, we investigated effects of NF-B inhi-
bitors on [Ca
2+]i mobilization and platelet aggregation.
BAY11-7082, at low concentration of up to 10 μM, not
only significantly attenuated [Ca
2+]i mobilization, but
also inhibited platelet aggregation stimulated by collagen
(Figure 4A, B). In addition, preincubation of platelets
with the inhibitors, SQ22536 (100 μM) and H89 (5 μM),
both strongly reversed sesamol’s inhibition of [Ca
2+]i
mobilization and platelet aggregation (Figure 4A, B).
Taken together, our data suggest that NF-B is involved
in [Ca
2+]i mobilization and platelet aggregation, and
sesamol’s inhibition of NF-B is mediated, at least
partly, by a cyclic nucleotide-dependent pathway.
Discussion
The function of NF-B has been extensively studied in
nucleated cells. Diverse stimuli, including cytokines,
viral infection, UV radiation, and free radicals, can
induce NF-B activation. Genes regulated by NF-B
include those involved in inflammation, cell survival, dif-
ferentiation, and proliferation responses [12]. Therefore,
NF-B is an attractive target for therapeutic interven-
tions against cancer and inflammatory diseases. Platelets
are anucleated cells; however, several studies found that
platelets express transcription factors such as steroid/
nuclear receptors [17], a glucocorticoid receptor [18],
and peroxisome proliferator-activated receptors (PPARs)
[19]. Those findings suggest that transcription factors
can exert non-genomic functions on platelets.
It was shown that IBa is phosphorylated and
degraded after platelet activation [13]. The functional
significance of NF-B is still not clear. The question
remains as to whether or not this transcription factor is
functionally present in a novel way, unrelated to tran-
scriptional regulation, in anucleated platelets. It was
demonstrated that pretreatment with an NF-B inhibi-
tor prevented multiple platelet activation mechanisms,
such as platelet adhesion to fibrinogen, integrin aIIbb3
activation, P-selectin expression, and thromboxane A2
(TxA2) formation [20]. NF-B signaling also inhibited
the phosphorylation of extracellular signal-regulated
kinases (ERKs), which regulate cytosolic phospholipase
A2 (cPLA2) activity, the main enzyme responsible for
the release of AA, which is converted to form TxA2 in
platelets [20]. Moreover, three IKK (a, b,a n dg)f a m i l y
members are expressed in platelets, with the b form
being even more strongly expressed in platelets than
either a or g form. In the present study, IKKb phos-
phorylation, IBa degradation, and p65 phosphorylation
were also observed in collagen-activated platelets; our
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Figure 3 NF-B regulates phospholipase Cg2( P L C g2)
phosphorylation, and protein kinase C (PKC) activity in
collagen-activated platelets. Washed platelets (1.2 × 10
9/ml) were
preincubated with or without BAY11-7082 (10 and 50 μM), followed
by the addition of collagen (1 μg/ml) to trigger (A)I Ba
degradation for 10 min or (B) PLCg2 and (C) PKC substrate (p47)
phosphorylation for 5 min. Cells were collected, and subcellular
extracts were analyzed by immunoblotting. Data are presented as
the means ± S.E.M. (n = 4). **p< 0.01 and ***p< 0.001, compared to
the control group (resting);
#p< 0.05 and
###p< 0.001, compared to
the collagen group.
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Page 6 of 10[13,20]. Furthermore, pretreatment with the NF-B inhi-
bitor, BAY11-7082, clearly attenuated PLC-PKC activa-
tion, [Ca
2+]i mobilization, and platelet aggregation
(Figures 3 and 4). PLC is a key enzyme in signal
transduction [21]. There are six major families of PLC
enzymes which consist of at least 13 PLC isoforms:
PLCb (1~4), PLCg (1 and 2), PLCδ ( 1 ,3 ,a n d4 ) ,P L C ε
(1), PLCζ (1), and PLCh (1 and 2) [21]. PLCg2i s
Figure 4 Effects of sesamol on the inhibition of [Ca
2+]i mobilization and platelet aggregation in the presence of various inhibitors in
collagen-activated platelets. Washed platelets were preincubated with sesamol (25 μM) or 0.5% DMSO in the presence of BAY11-7082 (10
μM), SQ22536 (100 μM), or H89 (5 μM), followed by the addition of collagen (1 μg/ml) to trigger (A) [Ca
2+]i mobilization and (B) platelet
aggregation for 6 min as described in “Methods”. The profiles (A and B) are representative examples of four similar experiments.
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Page 7 of 10involved in antigen-dependent signaling in B cells and
collagen-dependent signaling in platelets [22]. Activation
of PLCg2 results in the degradation of phosphoinosi-
tides, notably, phosphatidylinositol 4,5-bisphosphate
(PI4,5-P2), resulting in the production of the second
messengers, IP3 and DAG [23]. IP3 triggers an increase
in intracellular Ca
2+ from Ca
2+-storage sites (i.e., the
dense tubular system, DTS) in platelets. DAG activates
PKC-inducing protein phosphorylation (p47) (Figure 5).
PKC activation represents a strategy adopted by cells to
allow selected responses to specific activating signals in
distinct cellular compartments [24]. Our results suggest
that NF-B may be a novel upstream regulator of the
PLC-PKC cascade in activated platelets (Figure 5).
T h e s ed a t ai n d i c a t et h a tN F - B transcription factors
could have functions other than regulating gene expres-
sion and that anucleated platelets are a relevant model
for investigating these functions. Furthermore, our data
do not exclude other potential, yet-unidentified func-
tions of NF-B family members in platelets.
In human platelets, cAMP or cGMP plays a crucial
role in platelet inhibition. The effect of cAMP is
mediated via cAMP-dependent protein kinase (PKA).
PKA is a tetrameric holoenzyme consisting of a regula-
tory (PKAr) subunit dimer and two catalytic (PKAc)
subunits. Elevation of cAMP levels and binding of
cAMP to PKAr causes dissociation of the kinase com-
plex and release of free active catalytic subunits [25].
Although PKA is mainly activated by cAMP, a fraction
of total cellular PKA forms a complex with NF-B-IB
proteins and may be released upon NF-B activation by
different stimuli [26,27]. Recently, Gambaryan et al. [27]
have reported that PKA is also activated through
cAMP-independent mechanisms, which involves to be
Figure 5 The hypothesis of inhibitory signaling of sesamol in platelet activation. Collagen binds to its receptors, and then activates both
the PLCg2-DAG-PKC and NF-B pathways. Activated phospholipase Cg2 (PLCg2) catalyses phosphatidylinositol 4,5-bisphosphate (PI4,5-P2) into
1,2-diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG activates protein kinase C (PKC), followed by phosphorylation of a 47-kDa
protein (p47). IP3 induces the release of Ca
2+ from the dense tubular system (DTS). On the other hand, IKKb activates NF-B signaling including
IBa degradation and p65 phosphorylation, which further activates the PLCg2-PKC pathway. Sesamol can activate cyclic AMP-protein kinase A
(PKA), followed by inhibition of both the PLCg2 and NF-B cascade (i.e., IKKb), and finally inhibits platelet activation.
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Page 8 of 10dissociated the PKAc from NF-B-IB-PKAc complex
by triggering IKKb phosphorylation in thrombin- and
collagen-activated platelets. This effect is taken as a
novel feedback inhibitory mechanism for prevention of
undesired platelet activation. In a previous study [11],
we showed that sesamol increases cAMP formation and
phosphorylates vasodilator-stimulated phosphoprotein
(VASP), which was obviously reversed in the presence
of SQ22536. In the present study, sesamol markedly
inhibited NF-B activation (i.e., IKKb phosphorylation)
(Figure 1) in collagen-stimulated platelets. These results
suggested that sesamol activates PKA through a classical
cAMP-dependent mechanism, which phosphorylates
substrate proteins involved in platelet inhibitory path-
ways. Herein, we propose a novel platelet inhibitory
pathway of inhibiting NF-B activation by cAMP/PKA
(Figure 5). However, our experiments do not completely
rule out the possibility that other, yet-unidentified
kinases besides cAMP/PKA are involved in sesamol-
mediated inhibition of NF-B activation.
Conclusions
In conclusion, the most important findings of this study
demonstrate for the first time that the antiplatelet activ-
ity of sesamol may involve an increase in cAMP/PKA,
followed by inhibition of NF-B-PLC-PKC signaling
events, which leads to inhibition of [Ca
2+]i mobilization,
and finally inhibition of platelet aggregation. Therefore,
sesamol may represent an increased therapeutic poten-
tial to treat such thromboembolic disorders. Because
platelet activation is not only linked to hemostasis, but
also has a relevant role in inflammation and metastasis,
our present data demonstrating that inhibition of NF-B
interferes with platelet function may have a great impact
when these types of drugs are considered for treating
cancer and various inflammatory diseases.
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